AVIR — Atea Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1593899 ·
Last close
$5.16
Market Cap
$413.46M
52W High
$6.45
52W Low
$2.87
ADV30
282,634
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -35,099,000 | -32,933,000 | 232,282,000 | 76,548,000 | 28,124,000 |
| Mar 2026 | 0 | — | -48,008,000 | -45,440,000 | 267,076,000 | 79,317,000 | 33,367,000 |
| Dec 2025 | 0 | — | -54,934,000 | -44,867,000 | 315,218,000 | 95,713,000 | 39,784,000 |
| Sep 2025 | 0 | — | -45,567,000 | -42,049,000 | 342,963,000 | 77,344,000 | 27,183,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-147,859,000
Investing CF
$132,923,000
Financing CF
$-25,141,000
CapEx
—
Dividends Paid
—
Buybacks
$-25,780,000
EPS Diluted TTM
$-2.11
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-568,009,000
Inventory
—
Receivables
—
ST Investments
$176,689,000
EBIT TTM
$-189,854,000
Pretax Income TTM
$-175,832,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -180,887,000 | -158,349,000 | 315,218,000 | 39,784,000 | 275,434,000 | -132,031,000 |
| Dec 2024 | 0 | -192,950,000 | -168,385,000 | 464,668,000 | 25,801,000 | 438,867,000 | -135,499,000 |
| Dec 2023 | 0 | -164,162,000 | -135,956,000 | 594,968,000 | 39,776,000 | 555,192,000 | -85,395,000 |
| Dec 2022 | 0 | -130,650,000 | -115,909,000 | 666,708,000 | 26,136,000 | 640,572,000 | -120,982,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-169,517,000
OpCashFlow TTM
—
Assets (Latest)
$267,076,000
Forward EPS
$-1.48
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $5.16 · call volume: 44 · put volume: 10
Expected Move to 2026-10-16:
±$1.23
(23.86%) —
implied range
$3.93 –
$6.39
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MPLT | MapLight Therapeutics, Inc. | $399.40M | $9.15 | — |
| NIKA | NIKA PHARMACEUTICALS, INC | $429.91M | $0.41 | — |
| DMAC | DiaMedica Therapeutics Inc. | $431.94M | $8.01 | — |
| CTNM | Contineum Therapeutics, Inc. | $434.39M | $13.18 | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $442.01M | $8.61 | — |
News headlines (Yahoo Finance, 1h cache)
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
2026-09-08 11:00 · Yahoo
Atea (AVIR) Q2 2026 Earnings Call Transcript
2026-08-19 21:13 · Yahoo
Atea Pharmaceuticals Q2 Earnings Call Highlights
2026-08-12 22:04 · Yahoo
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
2026-08-05 11:00 · Yahoo
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
2026-07-29 09:45 · Yahoo
Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial
2026-07-28 12:27 · Yahoo
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
2026-07-28 11:00 · Yahoo
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
2026-06-25 11:00 · Yahoo
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
2026-06-18 16:00 · Yahoo
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL C
2026-05-27 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.